Skip Navigation


NDT Advance Access originally published online on June 2, 2007
Nephrology Dialysis Transplantation 2007 22(10):2838-2848; doi:10.1093/ndt/gfm323
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
22/10/2838    most recent
gfm323v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ro, Y.
Right arrow Articles by Tomino, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ro, Y.
Right arrow Articles by Tomino, Y.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2007]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org


Inhibitory effects of matrix metalloproteinase inhibitor ONO-4817 on morphological alterations in chlorhexidine gluconate-induced peritoneal sclerosis rats

Yuuki Ro, Chieko Hamada, Masanori Inaba, Hiroaki Io, Kayo Kaneko and Yasuhiko Tomino

Division of Nephrology, Department of Internal Medicine, Juntendo University School of Medicine, Tokyo, Japan

Correspondence and offprint requests to: Dr Yasuhiko Tomino, Professor, Division of Nephrology, Department of Internal Medicine, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan. Email: yasu{at}med.juntendo.ac.jp



  Abstract

Background. The activity of gelatinase, matrix metalloproteinase-2, in effluent was increased in peritoneal dialysis patients with encapsulated peritoneal sclerosis (EPS) and in chlorhexidine gluconate-induced peritoneal sclerosing (PS) animal models. The objective of the present study was to investigate the effect of matrix metalloproteinase inhibitor (ONO-4817), an anticancer agent with anti-angiogenesis and anti-infiltration effects, on the development of peritoneal fibrosis in chlorhexidine gluconate-induced PS rats.

Methods. Forty-five Sprague–Dawley (S–D) rats were intraperitoneally injected with saline as control (n = 15) or with chlorhexidine gluconate (CH) (1.5 ml/100 g) in the CH group (n = 15). ONO-4817 (5 mg/rat) was administered intravenously to CH rats (the ONO-4817 group, n = 15) from initiation to the end of the study. After 22 days of ONO-4817 administration, the rats were sacrificed and the parietal peritoneum was harvested. The gene expressions of transforming growth factor-β (TGF-β), {alpha}-smooth muscle actin ({alpha}-SMA) and type I collagen in the peritoneum were analysed by the reverse transcription-polymerase chain reaction (RT–PCR). Peritoneal tissues were also evaluated immunohistologically.

Results. ONO-4817 significantly inhibited thickening of the submesothelial layer and accumulation of type I collagen in the peritoneum. ONO-4817 also prevented increases of the number of macrophages and blood vessels. The expressions of TGF-β, {alpha}-SMA and type I collagen in the peritoneum were markedly suppressed in ONO-4817-treated rats.

Conclusion. It appears that the administration of the MMP inhibitor ONO-4817 might be a new approach to the amelioration of PS.

Keywords: angiogenesis; cell infiltration; continuous ambulatory peritoneal dialysis (CAPD); matrix metalloproteinases (MMP); sclerosing peritonitis

Received for publication: 9. 4.06
Accepted in revised form: 2. 5.07


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Am. J. Physiol. Renal Physiol.Home page
K. Kurata, S. Maruyama, S. Kato, W. Sato, J.-i. Yamamoto, T. Ozaki, A. Nitta, T. Nabeshima, Y. Morita, M. Mizuno, et al.
Tissue-type plasminogen activator deficiency attenuates peritoneal fibrosis in mice
Am J Physiol Renal Physiol, December 1, 2009; 297(6): F1510 - F1517.
[Abstract] [Full Text] [PDF]

Home page
 pdiHome page
A. M. Summers
ENCAPSULATING PERITONEAL SCLEROSIS -- HAVE WE FOUND THE PERPETRATOR?
Perit. Dial. Int., September 1, 2009; 29(5): 499 - 501.
[Full Text] [PDF]

Home page
 pdiHome page
H. Saito, M. Kitamoto, K. Kato, N. Liu, H. Kitamura, K. Uemura, F. Nogaki, T. Takeda, N. Mori, and T. Ono
TISSUE FACTOR AND FACTOR V INVOLVEMENT IN RAT PERITONEAL FIBROSIS
Perit. Dial. Int., May 1, 2009; 29(3): 340 - 351.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.